THE HISTORY OF PSMA THERANOSTICS in this months JNM jnm.snmjournals.org/content/63/3/3… I think the 2022 headline will be FDA approval of Lu-177 PSMA-617 PCF Science Howard Soule Andrea Miyahira ProsTIC

🚨FierceBiotech's Fierce 15 is now live! This year's list features companies pushing the envelope in the lab, clinic and boardroom. fiercebiotech.com/special-report…

After a difficult three years, #biotech financing may slowly be returning to health. 🙏 Thank you dough M Bio Stocks™ Pharmdca HODOR Andre-ACGT quantumup etc. for your really good content on X. nature.com/articles/s4158…

Today, we're celebrating great news for the future of #cancer patients! The worldwide development and commercialization rights for our first-i-class, peptide-based #radioligandtherapy programs have exclusively been licensed to ITM Isotope Technologies Munich SE! 🎉 bit.ly/3zhOcUE #biotech

We have been proud to do some of the first CA-IX peptide Ga-68 PET/CT and Lu-177 therapy Peter Mac Cancer Centre Look forward to the next chapter: biospace.com/press-releases… jnm.snmjournals.org/content/early/…

The latest biannual #EJNMMI Radiopharmacy & Chemistry joint Editorial highlighting exciting new research reported in the #radiochemistry and #radiopharmacy literature during the first half of 2024 is out now. Written by our Eds, read it #OpenAccess here: ejnmmipharmchem.springeropen.com/articles/10.11…

Great targeted radiopharmaceuticals (TRT) landscape analysis from OPCO! A lot of people view this segment as the next ADC but so far it has been difficult to expand beyond SSTR2 and PSMA.

ADC LANDSCAPE Lots of players....if interested to differentiate explore the following 👇 💡🥼Novel Approaches: ✅ Novel Payloads ✅ Dual/Multi-Payload ADCs ✅ Novel ADC Formats ✅ Tumor Microenvironment Targeting ✅ Alternative Linkers ✅ Combos ✅ Tumor-Specific Antigen

Sales of ADCs reached $10B+ in 2023 with 4 blockbusters **AZ paid upfront $1.35B (total deal $7B) to Daiichi for Enhertu in 2019**

Should Lu-PSMA radiopharmaceutical therapy be used in earlier lines of therapy rather than after an ARPI or docetaxel? ASCO Daily News: dailynews.ascopubs.org/do/integrating… Arun Azad

The biotech report that Tim Opler's team at Stifel put out this afternoon is a banger. Some slides on China's impact to $XBI. 1/3 of external molecules brought in by big pharma are now coming from China (from 0 in 2019).

Timing and size of LOEs for the top Pharma products by 2024E sales A significant portion of current Pharma revenue comes from drugs with medium-term LOE risk (i.e. by 2028) Some takeaways as we head into JPM:

This work really started quite some years ago, but new insights and new collaborators gave this an exciting kick, so thanks Chemistry for publishing our study on synergistic Au and doxorubicin anticancer activities!

✨Alpha Emitters and Where to Find Them! ☢️ Are you thinking about working with alpha emitters but unsure where to start? We are happy to share our "Alpha Atlas" − a global map of production centers and suppliers of alpha-particle emitters! 🌎 Link to the full version below👇🏻

💼 PHARMA M&A IN 2025 A SIGNALS OF STRATEGIC SHIFTS Recent biotech M&A reveals interesting trends: 🔹 $JNJ $14.6B acquisition of $ITCI, completed in Q4 2024, secures Caplyta (lumateperone) for schizophrenia and bipolar disorder, with potential expansion into depression

Join us before iSRS 2025 for a series of pre-symposium workshops on Sunday, May 11, from 9:15-16:45! The first workshop “Alpha Emitters for the Curious and Cautious: Everything you Want to Know About Them but Are Afraid to Ask” will be from 9:15-12:00. Hope to see you there!

I'm excited to see this patent review on the development of FAPI imaging and theranostic agents published. Great work from Jason Witek, who led the project, and Prof. Scott ScottLab and Prof. Viglianti, who worked on the review with us. tandfonline.com/doi/full/10.10…

#VIOLET Study of Terbium-161 (Tb-161) Beta/Auger therapy ASCO #ASCO25 First prospective trial of Terbium-161 in any tumour type 🟣 30 patient trial in prostate cancer. No dose limiting toxicities at highest level of radioactivity (7.4 GBq) 🟣 Very few side effects: 1 grade 3

Stakeholders of theranostics: An interview with Richard Zimmermann about the golden age of nuclear medicine. ow.ly/uWZx50VKMgF #NuclearMedicine #Theranostics #RPTherapy

Does race impact outcomes to #LuPSMA? Pleased to share our multi-institutional retrospective study (N=650pts) looking at this Q published in Cancers: mdpi.com/2072-6694/17/1… Dana-Farber Lank Center for Genitourinary Oncology Heather Jacene Thomas Ng